---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-099485"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:36:11.315751+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics reports complete response in first lymphoma patient treated with MT-601 after CAR T relapse

## Summary
- First APOLLO trial patient with DLBCL, after 4 prior therapies including CAR T, achieved complete metabolic response at 8 weeks post 2nd MT-601 infusion.
- MT-601 dosed at 200 million cells without prior lymphodepletion; no treatment-related adverse events above Grade 1.
- Up to 60% of CAR T patients relapse within one year, underscoring potential of MT-601 in this setting.
- Phase 1 APOLLO trial continues to enroll additional participants to evaluate safety and efficacy.

## SEC filing metadata
- accession: 0001104659-23-099485
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465923099485/0001104659-23-099485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465923099485/tm2325824d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-099485
- JSON: https://secwatch.observer/filing/0001104659-23-099485.json
- Plain text: https://secwatch.observer/filing/0001104659-23-099485.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.